biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
~156 kDa
species reactivity
mouse, rat, human
concentration
1 mg/mL
technique(s)
western blot: 1:500-1:1000
isotype
IgG
immunogen sequence
(E-H-Y-V-H)
NCBI accession no.
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... MET(4233)
General description
MET/c-Met (mesenchymal-epithelial transition factor) is a tyrosine kinase receptor , that is located on human chromosome 7q31.
Receptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
Immunogen
Peptide sequence around aa. 1347-1351 (E-H-Y-V-H), according to the protein MET.
Biochem/physiol Actions
MET/c-Met (mesenchymal-epithelial transition factor) controls several biological processes like cell scattering, survival, proliferation, migration and c-MET signaling.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品?
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
The c-Met receptor: Implication for targeted therapies in colorectal cancer
Safaie Qamsari E, et al.
Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine, 39(5) (2017)
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
Baljevic M, et al.
Annals of Hematology, 96(6), 977-985 (2017)
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
Choueiri TK, et al.
Journal of Clinical Oncology, 31(2), 181-186 (2013)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持